GLUE Stock Forecast: Monte Rosa Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.64
−3.03% on the day

The median 12-month analyst price target for Monte Rosa Therapeutics, Inc. is $26. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 48 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$738.3M
Ticker Nerd rank
48/ 100
Median analyst target
$26
Analysts covering
10
Revenue$9.0M−61.3% y/y
Operating income−$49.1M
Net income−$43.4M
Free cash flow−$48.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.8%
1M
−23.9%
YTD
−44.9%
1Y
−36.1%
From 52W high
−65.9%
From 52W low
0.0%
$9
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Monte Rosa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
48/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
80
Value
71
Quality
69
Momentum
55
Volatility
44
Issuance
39
Accruals
19
Growth
15

Revisions (80): Analysts have, on balance, been raising their forecasts.

Growth (15): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GLUE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GLUE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30$35$40Jan 26Apr 26Jul 26Oct 26GLUEHigh $37Median $26Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10
Buy
0
Hold
0
Sell
$15
Low
$26
Median
$37
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
6 Nov 2026Wells FargoMaintainsOverweight$27 → $25
12 Oct 2026UBSAssumesBuy$17 → $19
5 Oct 2026HC Wainwright & Co.ReiteratesBuy$25
1 Oct 2026HC Wainwright & Co.InitiatesBuy$25
9 Sept 2026WedbushReiteratesOutperform$27
25 Aug 2026GuggenheimReiteratesBuy$28
7 Aug 2026GuggenheimMaintainsBuy$35 → $28
7 Aug 2026JP MorganMaintainsOverweight$31 → $27
7 Aug 2026Wells FargoMaintainsOverweight$29 → $27
3 Aug 2026WedbushMaintainsOutperform$37 → $27
30 June 2026GuggenheimMaintainsBuy$30 → $35
11 May 2026JP MorganMaintainsOverweight—
18 Mar 2026GuggenheimMaintainsBuy—
18 Mar 2026Wells FargoMaintainsOverweight—
14 Jan 2026Piper SandlerReiteratesOverweight—
8 Jan 2026GuggenheimMaintainsBuy—
8 Jan 2026Wells FargoMaintainsOverweight—
16 Dec 2025Wells FargoUpgradeOverweight—
7 Nov 2025Wells FargoMaintainsEqual-Weight—
21 Mar 2025WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GLUE.

Market Radar

This page is one stock. Monday covers all of them.

GLUE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GLUE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Monte Rosa Therapeutics, Inc. returned −36.1% against +6.9% for the S&P 500, dividends included.

GLUE vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Jan 26Apr 26Jul 26Oct 26GLUES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GLUE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
10.5×

Cheaper than 12% of US stocks

Price / book
1.5×

Cheaper than 54% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−35.3%

Higher than 26% of US stocks

Return on assets
−16.3%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Monte Rosa Therapeutics, Inc. has a market value of $738.3M and an enterprise value of $196.8M.

  • Revenue in the twelve months to 30 June 2026: $28.7M. The latest quarter shrank 61.3% year on year.

  • Net income over the same four quarters: −$161.1M, a −560.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.18.

  • Free cash flow in the twelve months to 30 June 2026: −$32.1M.

  • Shares outstanding: 85.2M.

  • Monte Rosa Therapeutics, Inc. employs 185 people — $155K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

GLUE and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GLUEMonte Rosa Therapeutics, Inc.$738.3M48
OBXObsidian Therapeutics, Inc.$740.7M36
RIGLRigel Pharmaceuticals, Inc.$741.7M84
AURAAura Biosciences, Inc.$710.3M61
ARDXArdelyx, Inc.$751.6M57
SNDXSyndax Pharmaceuticals, Inc.$757.9M58
ORICOric Pharmaceuticals, Inc.$761.9M53

Take a look at GLUE’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Monte Rosa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about GLUE

What is the GLUE stock price forecast for 2026-2027?

The median 12-month analyst price target for Monte Rosa Therapeutics, Inc. is $26, with estimates ranging from $15 to $37. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GLUE stock a buy right now?

Of the 10 analysts covering Monte Rosa Therapeutics, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Monte Rosa Therapeutics, Inc. 48 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GLUE?

As at 21 Nov 2026, Monte Rosa Therapeutics, Inc. ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (80 of 100).

Will GLUE stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts is $26, and Ticker Nerd's factor model ranks Monte Rosa Therapeutics, Inc. 48 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GLUE stock forecast for 2030?

No analyst covering Monte Rosa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GLUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $37 over the next 12 months.

How has GLUE stock performed over the past year?

Monte Rosa Therapeutics, Inc. returned -36.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Monte Rosa Therapeutics, Inc. do?

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degrader medicines that selectively eliminate disease-causing proteins. Its current pipeline includes orally available small-molecule candidates for oncology, autoimmune and inflammatory disorders, and other serious diseases, using the body’s natural protein-degradation machinery to address targets that are difficult to treat with conventional drugs.

Company

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing molecular glue degrader medicines that selectively eliminate disease-causing proteins. Its current pipeline includes orally available small-molecule candidates for oncology, autoimmune and inflammatory disorders, and other serious diseases, using the body’s natural protein-degradation machinery to address targets that are difficult to treat with conventional drugs. The company’s research is centered on precision medicine approaches that combine chemistry, structural biology, proteomics, and computational methods to identify and optimize novel therapies. Monte Rosa Therapeutics, Inc. operates in the biotechnology sector, where targeted protein degradation is an important area of drug discovery and development.

CEO Dr. Markus Warmuth M.D. · 185 employees · United States · https://www.monterosatx.com